CN115776889A - 用于治疗非小细胞肺癌的egfr tki - Google Patents

用于治疗非小细胞肺癌的egfr tki Download PDF

Info

Publication number
CN115776889A
CN115776889A CN202180037402.7A CN202180037402A CN115776889A CN 115776889 A CN115776889 A CN 115776889A CN 202180037402 A CN202180037402 A CN 202180037402A CN 115776889 A CN115776889 A CN 115776889A
Authority
CN
China
Prior art keywords
egfr tki
egfr
pharmaceutically acceptable
acceptable salt
tki
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180037402.7A
Other languages
English (en)
Chinese (zh)
Inventor
Y·鲁卡岑科夫
S·乔治乌
F·博雷利尼
H·曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to CN202610610034.5A priority Critical patent/CN122376595A/zh
Publication of CN115776889A publication Critical patent/CN115776889A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180037402.7A 2020-05-27 2021-05-26 用于治疗非小细胞肺癌的egfr tki Pending CN115776889A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202610610034.5A CN122376595A (zh) 2020-05-27 2021-05-26 用于治疗非小细胞肺癌的egfr tki

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063030372P 2020-05-27 2020-05-27
US63/030372 2020-05-27
PCT/EP2021/063992 WO2021239786A1 (en) 2020-05-27 2021-05-26 Egfr tkis for use in the treatment of non-small cell lung cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202610610034.5A Division CN122376595A (zh) 2020-05-27 2021-05-26 用于治疗非小细胞肺癌的egfr tki

Publications (1)

Publication Number Publication Date
CN115776889A true CN115776889A (zh) 2023-03-10

Family

ID=76181131

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180037402.7A Pending CN115776889A (zh) 2020-05-27 2021-05-26 用于治疗非小细胞肺癌的egfr tki
CN202610610034.5A Pending CN122376595A (zh) 2020-05-27 2021-05-26 用于治疗非小细胞肺癌的egfr tki

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202610610034.5A Pending CN122376595A (zh) 2020-05-27 2021-05-26 用于治疗非小细胞肺癌的egfr tki

Country Status (14)

Country Link
US (3) US20210369709A1 (enExample)
EP (1) EP4157267B1 (enExample)
JP (1) JP2023529812A (enExample)
KR (1) KR20230017830A (enExample)
CN (2) CN115776889A (enExample)
AU (1) AU2021279171A1 (enExample)
BR (1) BR112022023519A2 (enExample)
CA (1) CA3183434A1 (enExample)
DK (1) DK4157267T3 (enExample)
FI (1) FI4157267T3 (enExample)
IL (1) IL298216A (enExample)
MX (1) MX2022014903A (enExample)
TW (1) TW202216149A (enExample)
WO (1) WO2021239786A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121177212A (zh) * 2025-11-25 2025-12-23 中南大学湘雅二医院 一种用于治疗egfr突变非小细胞肺癌脑膜转移的药物、应用、药盒及药物的制备方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022526159A (ja) 2019-03-29 2022-05-23 アストラゼネカ・アクチエボラーグ 非小細胞肺がんの治療に使用するためのオシメルチニブ
US12649792B2 (en) 2019-05-06 2026-06-09 Brown University Bispecific antibodies against CHI3L1 and PD1 with enhanced T cell-mediated cytotoxic effects on tumor cells
WO2024059962A1 (en) * 2022-09-19 2024-03-28 Shanghai Allist Pharmaceuticals Co., Ltd. Pharmaceutical composition and use thereof
WO2024118611A2 (en) * 2022-11-28 2024-06-06 Brown University Treatment of epidermal growth factor receptor mutant non-small cell lung cancer
CN117298116A (zh) * 2023-08-08 2023-12-29 江苏晨泰医药科技有限公司 盐酸佐利替尼制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946235B2 (en) * 2011-07-27 2015-02-03 Astrazeneca Ab 2-(2,4,5-substituted-anilino) pyrimidine compounds
CN110996962A (zh) * 2017-08-03 2020-04-10 诺华股份有限公司 第三代egfr酪氨酸激酶抑制剂和周期素d激酶抑制剂的治疗组合

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
HRP20110958T1 (hr) 2004-05-06 2012-01-31 Warner-Lambert Company Llc 4-fenilaminokinazolin-6-ilamidi
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
LT2964638T (lt) 2013-03-06 2017-12-27 Astrazeneca Ab Epidermio augimo faktoriaus receptoriaus aktyvinančių mutacijų formų chinazolino inhibitoriai
ES3069593T3 (en) 2013-08-23 2026-06-09 Neupharma Inc Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
US20170166598A1 (en) 2014-05-13 2017-06-15 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN105315259B (zh) 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物、其制备方法及应用
EP3205650B1 (en) 2014-10-11 2021-08-04 Shanghai Hansoh Biomedical Co., Ltd. Egfr inhibitor, and preparation and application thereof
EP3929190B1 (en) 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
CN111170998B (zh) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
AU2015360360B2 (en) 2014-12-11 2020-06-25 Beta Pharma (Shanghai) Co., Ltd. Substituted 2-anilinopyrimidine derivatives as EGFR modulators
CN107614503B (zh) 2015-04-29 2020-03-10 广东众生药业股份有限公司 稠环或三环芳基嘧啶化合物用作激酶抑制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946235B2 (en) * 2011-07-27 2015-02-03 Astrazeneca Ab 2-(2,4,5-substituted-anilino) pyrimidine compounds
US9732058B2 (en) * 2011-07-27 2017-08-15 Astrazeneca Ab 2-(2,4,5-substituted-anilino)pyrimidine compounds
CN110996962A (zh) * 2017-08-03 2020-04-10 诺华股份有限公司 第三代egfr酪氨酸激酶抑制剂和周期素d激酶抑制剂的治疗组合

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ASTRA ZENECA: "AZD9291Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy", Retrieved from the Internet <URL:https://clinicaltrials.gov/study/NCT02511106?id=NCT02511106&rank=1&tab=history&a=36#version-content-panel> *
HUA CHENG等: ""A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer"", 《LUNG CANCER (AMSTERDAM, NETHERLANDS)》, vol. 137, 5 August 2019 (2019-08-05), pages 7 - 13 *
IVANA SULLIVAN等: ""Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience"", 《THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE》, vol. 10, no. 6, 26 October 2016 (2016-10-26), pages 549 - 565 *
石乐明: "《大数据与精准医学》", vol. 1, 31 December 2017, 上海交通大学出版, pages: 255 - 257 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121177212A (zh) * 2025-11-25 2025-12-23 中南大学湘雅二医院 一种用于治疗egfr突变非小细胞肺癌脑膜转移的药物、应用、药盒及药物的制备方法

Also Published As

Publication number Publication date
JP2023529812A (ja) 2023-07-12
CA3183434A1 (en) 2021-12-02
IL298216A (en) 2023-01-01
AU2021279171A1 (en) 2023-02-02
EP4157267A1 (en) 2023-04-05
DK4157267T3 (da) 2026-08-03
US20210369709A1 (en) 2021-12-02
WO2021239786A1 (en) 2021-12-02
KR20230017830A (ko) 2023-02-06
US20240423978A1 (en) 2024-12-26
US20250325543A1 (en) 2025-10-23
MX2022014903A (es) 2023-01-04
EP4157267B1 (en) 2026-07-08
CN122376595A (zh) 2026-07-14
TW202216149A (zh) 2022-05-01
FI4157267T3 (fi) 2026-08-12
BR112022023519A2 (pt) 2022-12-20

Similar Documents

Publication Publication Date Title
US20240423978A1 (en) EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL LUNG CANCER
AU2017329090B9 (en) Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
RU2563193C2 (ru) Комбинации ингибитора pi3k и ингибитора мек
US12465608B2 (en) Osimertinib for use in the treatment of non-small cell lung cancer
JP2024509823A (ja) アムセネストラントおよびパルボシクリブによる乳がんの処置
US20230056604A1 (en) Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
EP4583983A1 (en) Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
TW202408514A (zh) 用於治療癌症的表皮生長因子受體酪胺酸激酶抑制劑
US20210161897A1 (en) Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
RU2774612C2 (ru) Терапевтические комбинации, содержащие ингибитор raf и ингибитор erk
KR20250044679A (ko) 암 치료를 위한 hgf-수용체 억제제와 병용의 상피 성장 인자 수용체 티로신 키나아제 억제제
EA052374B1 (ru) Осимертиниб для применения в лечении немелкоклеточного рака легкого

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination